{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:55:42Z","timestamp":1769601342672,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.clml.2019.07.001","type":"journal-article","created":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T11:49:07Z","timestamp":1562327347000},"page":"e573-e580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Lymphoma-Associated Macrophage to Hodgkin-Reed-Sternberg Cell Ratio Is a Poor Prognostic Factor in Classic Hodgkin Lymphoma Patients"],"prefix":"10.1016","volume":"19","author":[{"given":"V\u00edt","family":"Proch\u00e1zka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1\u0161","family":"Papaj\u00edk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tereza","family":"D\u00fd\u0161kov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Dihel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sv\u011btlana","family":"Brychtov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzana","family":"Prouzov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Kriegov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Luk\u00e1\u0161ov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Han\u00e1\u010dkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.07.001_bib2","series-title":"Cancer Incidence 2010 in the Czech Republic","year":"2010"},{"key":"10.1016\/j.clml.2019.07.001_bib3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1200\/JCO.2013.53.1194","article-title":"Treatment of Hodgkin lymphoma: a 50-year perspective","volume":"32","author":"Canellos","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.07.001_bib4","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1517\/14656566.2014.909411","article-title":"Pharmacotherapy of Hodgkin lymphoma: standard approaches and future perspectives","volume":"15","author":"Eichenauer","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clml.2019.07.001_bib5","doi-asserted-by":"crossref","first-page":"428","DOI":"10.5507\/bp.2013.022","article-title":"Reduced relative dose intensity of primary chemotherapy does not influence prognosis of patients with Hodgkin lymphoma","volume":"158","author":"Raida","year":"2014","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"issue":"suppl 4","key":"10.1016\/j.clml.2019.07.001_bib6","doi-asserted-by":"crossref","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","article-title":"ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Eichenauer","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2019.07.001_bib7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.6004\/jnccn.2018.0013","article-title":"NCCN Guidelines insights: Hodgkin lymphoma, version 1.2018","volume":"16","author":"Hoppe","year":"2018","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2019.07.001_bib8","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.3109\/10428194.2014.975804","volume":"56","author":"Belada","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2019.07.001_bib9","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2015.64.5648","article-title":"Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, International Prognostic Score\u00a0\u2265 3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 Intergroup Trial","volume":"34","author":"Carde","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2019.07.001_bib10","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1182\/blood-2018-99-115150","article-title":"Metabolic tumor volume and soluble cytokines levels in newly diagnosed Hodgkin lymphoma: what it brings into the staging precision?","volume":"132","author":"Prochazka","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.07.001_bib11","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2010.32.8401","article-title":"Molecular pathogenesis of Hodgkin lymphoma: increasing evidence of the importance of the microenvironment","volume":"29","author":"Steidl","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.07.001_bib12","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/asheducation.V2012.1.328.3798326","article-title":"New insights in the biology of Hodgkin lymphoma","volume":"2012","author":"K\u00fcppers","year":"2012","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2019.07.001_bib13","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1182\/blood-2014-07-537480","article-title":"Risk assessment in the management of newly diagnosed classical Hodgkin lymphoma","volume":"125","author":"Connors","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.07.001_bib14","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1200\/JCO.2011.39.9881","article-title":"Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome","volume":"31","author":"Greaves","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.07.001_bib15","series-title":"Automated image analysis revealed a high variability of CD30+ HRS cells density in classical nodular sclerosis Hodgkin lymphoma (abstract E1144)","author":"Prochazka","year":"2015"},{"key":"10.1016\/j.clml.2019.07.001_bib16","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/ejh.12583","article-title":"Tumour-associated mast cells in classical Hodgkin's lymphoma: correlation with histological subtype, other tumour-infiltrating inflammatory cell subsets and outcome","volume":"96","author":"Andersen","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2019.07.001_bib17","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.mayocp.2015.03.025","article-title":"Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: evaluation based on data from 1450 patients","volume":"90","author":"Tadmor","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2019.07.001_bib18","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bjh.14406","article-title":"Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients","volume":"180","author":"Bari","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.07.001_bib19","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hon.2295","article-title":"Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin lymphoma","volume":"35","author":"Gotti","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2019.07.001_bib20","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/cam4.585","article-title":"CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma","volume":"5","author":"Cuccaro","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2019.07.001_bib21","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/hon.2249","article-title":"Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment","volume":"35","author":"Cencini","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2019.07.001_bib22","doi-asserted-by":"crossref","first-page":"E2416","DOI":"10.3390\/ijms20102416","article-title":"Formation of the immunosuppressive microenvironment of classic Hodgkin lymphoma and therapeutic approaches to counter it","volume":"20","author":"Aldinucci","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clml.2019.07.001_bib23","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1158\/2159-8290.CD-16-0850","article-title":"Overcoming the immunosuppressive tumor microenvironment of Hodgkin lymphoma using chimeric antigen receptor T cells","volume":"7","author":"Ruella","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2019.07.001_bib24","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1158\/1078-0432.CCR-18-1133","article-title":"Targeting cancer cells and tumor microenvironment in preclinical and clinical models of Hodgkin lymphoma using the dual PI3K\u03b4\/\u03b3 inhibitor RP6530","volume":"25","author":"Locatelli","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2019.07.001_bib25","doi-asserted-by":"crossref","first-page":"e467","DOI":"10.1016\/S2352-3026(16)30108-9","article-title":"The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin lymphoma: a retrospective, European, multicentre cohort study","volume":"3","author":"Agostinelli","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2019.07.001_bib26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5301\/ijbm.5000312","article-title":"How immunologic and genetic biomarkers impact Hodgkin lymphoma classification, diagnosis, and management: a huge potential that yet needs to be exploited","volume":"33","author":"Carbone","year":"2018","journal-title":"Int J Biol Markers"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019304926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019304926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:32:59Z","timestamp":1761870779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019304926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S2152265019304926"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.07.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Lymphoma-Associated Macrophage to Hodgkin-Reed-Sternberg Cell Ratio Is a Poor Prognostic Factor in Classic Hodgkin Lymphoma Patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}